

February 2019 as a result of merging of all pediatric oncology units in the country. Among the 11 practicing pediatric hematologist/oncologists no one is dedicated specifically to PBTs. Since September 2017 we have started discussing all PBT cases (up to now 18 cases) through the telemedicine with St. Jude Children's Research Hospital (SJCRH). In Sept 2019 neuro-oncology multidisciplinary team was created with the involvement of local and foreign specialists. On a weekly basis the multidisciplinary team discusses all new and problematic cases. The team also concentrates on adaptation of diagnostic and treatment guidelines for pediatric CNS tumors, creation of educational materials for different stakeholders, and identification of current problems and their possible solutions. CONCLUSION: To the best of our knowledge this is the first report summarizing the current state of pediatric neuro-oncology in Armenia.

#### LINC-14. TREATMENT OF PEDIATRIC CNS TUMORS IN ARMENIA. 10 YEARS OF EXPERIENCE IN A 29 YEARS OLD RESOURCE-LIMITED SETTING

Martin Harutyunyan<sup>1,2</sup>, Lilit Sargsyan<sup>3</sup>, Samvel Iskanyan<sup>3</sup>, Lusine Hakobyan<sup>3</sup>, Ruzanna Papyan<sup>3</sup>, Gevorg Tamamyan<sup>3,1</sup>, Karen Bedirian<sup>2</sup>, Samvel Danielyan<sup>3</sup>, Armen Tananyan<sup>1</sup>, Manushak Avagyan<sup>1</sup>, Nune Karapetyan<sup>1</sup>, and Samvel Bardakhchyan<sup>3,1</sup>; <sup>1</sup>Yerevan State Medical University, Yerevan, Armenia, <sup>2</sup>City of Smile Charitable Foundation, Yerevan, Armenia, <sup>3</sup>Hematology Center after Prof. R. Yeolyan, Yerevan, Armenia

**BACKGROUND:** Pediatric CNS tumors are the most common solid childhood malignancies with many challenges facing optimal outcome due to multimodality complex therapies, abandonment, and long-term morbidity. In our three-decades young, country the field of neuro-oncology is in its infancy. **MATERIALS:** The aim of our study is to assess incidence, epidemiology and treatment outcomes of children diagnosed and treated with CNS tumors within the last 10 years (2009–2019) in the Chemotherapy Clinic of “Muratsan” Hospital Complex of Yerevan State Medical University. **RESULTS:** During these periods 20 patients with CNS tumors were treated in our clinic. 13 patients (65%) were diagnosed with medulloblastoma (2 patients were infants), two patients (10%) with optic pathway glioma, and 5 patients each with pilocytic astrocytoma, ATRT, ETANTR, DIPG, and glioblastoma. Five patients (3 patients with medulloblastoma, 1 patient with pilocytic astrocytoma, 1 patient with ATRT) had metastatic disease at the time of diagnosis. Seventeen patients (80%) had undergone surgery, 8 patients with medulloblastoma received chemo-RT with vincristine. Median follow up time was 15.5 months (range 5–94). Twelve patients (60%) are alive without evidence of disease. 5 patients had disease progression and three patients relapsed. From them, 3 patients died. Long-term survivors are mainly standard risk medulloblastoma patients. All medulloblastoma patients were treated according to HIT-MED guidelines. **CONCLUSION:** Here we report about the pediatric brain tumors of one of the main pediatric oncology units in Armenia for a period of 10 years. The numbers are quite small for firm conclusions, but it shows the emerging need for further research.

#### LINC-15. OUTCOME OF CHINESE CHILDREN WITH MEDULLOBLASTOMA: A MULTI-CENTER EXPERIENCE WITH RISK-ADAPTED THERAPY

Xiaofei Sun<sup>1</sup>, Anthony Pak-Yin Liu<sup>2</sup>, Qunying Yang<sup>1</sup>, Jian Wang<sup>1</sup>, Shaoxiong Wu<sup>1</sup>, Zijun Zhen<sup>1</sup>, Jingsheng Wang<sup>3</sup>, Haixia Guo<sup>4</sup>, Lian Jiang<sup>5</sup>, Xiaoli Ma<sup>6</sup>, Wenjun Weng<sup>7</sup>, Lihua Yang<sup>8</sup>, Libin Huang<sup>9</sup>, Juan Li<sup>10</sup>, and Godfrey Chi-Fung Chan<sup>2</sup>; <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, China, <sup>2</sup>Hong Kong Children's Hospital, Hong Kong SAR, China, <sup>3</sup>Shenzhen Children's Hospital, Shenzhen, China, <sup>4</sup>Southern Medical University Nanfang Hospital, Guangzhou, China, <sup>5</sup>Hebei Medical University the Fourth Hospital, Hebei, China, <sup>6</sup>Beijing Children's Hospital, Beijing, China, <sup>7</sup>Sun Yat-sen University Memorial Hospital, Guangzhou, China, <sup>8</sup>Southern Medical University Zhujiang Hospital, Guangzhou, China, <sup>9</sup>Sun Yat-sen University the First Affiliated Hospital, Guangzhou, China, <sup>10</sup>Guangdong 999 Brain Hospital, Guangzhou, China

**BACKGROUND:** Medulloblastoma is the commonest brain tumor in young children but literature on Chinese is scarce. We hereby present the outcome of children with medulloblastoma managed according to a risk- and age-stratified guideline from ten institutions across China. **METHODS:** Patients <18 years of age diagnosed with medulloblastoma between January 2016 and April 2019 were reviewed. Patients ≥3 years, stratified into average-risk (≤1.5cm<sup>2</sup> residual tumor, non-metastatic, non-anaplastic histology) and high-risk (others) groups, were treated with risk-adapted craniospinal irradiation (average-risk: 23.4Gy, high-risk: 36Gy), tumor boost, and chemotherapy (lomustine/cisplatin/vincristine). Patients <3 years (considered high-risk, other than patients with localized and desmoplastic/nodular histology) received chemotherapy (cyclophosphamide/vincristine, high-dose methotrexate, carboplatin/etoposide) with/without delayed irradiation. **RESULTS:** 112 patients were included with a median age at diagnosis of 6.5 years (range: 0.5–16.7). 16 patients (14.3%) had residual tumor >1.5cm<sup>2</sup>

and 36 (32%) had metastasis. Available data on histological subtype (n=87) were classic in 56 (64%), desmoplastic/nodular or extensive nodularity in 23 (26%), and large cell/anaplastic in 8 (9%). Molecular subgrouping (n=55) assigned tumors as WNT-activated (n=8, 15%), SHH-activated (n=17, 31%), Group 3 (n=12, 22%) and Group 4 (n=18, 33%). Respective 2-year EFS/OS for patients ≥3 and <3 years were 86.0±4.0%/96.4±2.1% and 57.8±12.6%/81.4±9.8% (EFS/OS p<0.001/p=0.009). Significant difference in outcome was also observed between patients with average-risk and high-risk disease (EFS/OS p=0.006/p=0.018). **CONCLUSION:** We demonstrated feasibility in protocolizing the inter-disciplinary treatment for medulloblastoma in China. This will serve as a prototype for the standardization of pediatric neuro-oncology care in the country.

#### LINC-16. MEDULLOBLASTOMA IN A BOY WITH RUBINSTEIN-TAYBI SYNDROME: A CASE REPORT

Regina M Navarro-Martin del Campo<sup>1,2</sup>, Juan Luis Soto-Mancilla<sup>3</sup>, Luis A Arredondo-Navarro<sup>3,2</sup>, Ana L Orozco-Alvarado<sup>1</sup>, and Fernando A Sanchez-Zubieta<sup>1</sup>; <sup>1</sup>Hospital Civil de Guadalajara Dr Juan I Menchaca”, Guadalajara, Jalisco, Mexico, <sup>2</sup>GAPNO, International Group, Mexico, <sup>3</sup>Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Guadalajara, Jalisco, Mexico

**BACKGROUND:** Rubinstein-Taybi syndrome (RTS) is characterized by multiple congenital anomalies and associated with mutations in CREBBP (70%) and EP300 (5–10%). Previous reports have suggested an increased incidence of benign and possibly also malignant tumors, but the correlation remains unclear. Here we present a case of a patient with RTS and medulloblastoma. **CLINICAL CASE:** A 5-year-old male presented with increased intracranial pressure. An MRI revealed a 4.2 x 4.7 cm mass in the midline of cerebellum arising from the floor of 4<sup>th</sup> ventricle. The patient underwent a complete resection and pathology revealed medulloblastoma, classic histology. Staging established no disseminated disease. At diagnosis, a peculiar phenotype consisting in mild mental retardation, microcephaly, down-slanting palpebral fissures, broad nasal bridge, highly arched palate, mild micrognathia, screwdriver incisors and wide thumbs and toes was noted. Clinical genetics evaluation was consistent with RTS. Karyotype was performed and normal. Further genetics testing was not done. Treatment consisted in 8 cycles of chemotherapy and craniospinal radiation (2300 cGy to spine, 5500 cGy Total). At the end of treatment, there was no evidence of disease. He was under surveillance for 33 months free of disease, but relapsed with a supratentorial meningeal disease that ultimately resulted in death. **CONCLUSION:** This report highlights the fact that pediatric medulloblastoma can be associated to RTS, in this case associated to classical histology and recurrent disease.

#### LINC-17. SIROLIMUS AS AN ALTERNATIVE TO SURGICAL RESECTION OF PEDIATRIC TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED BILATERAL SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: AN AFFORDABLE OPTION FOR PATIENTS FROM LOW-MIDDLE INCOME COUNTRIES

Patricia Orduña; UP-Philippine General Hospital, Manila, Philippines

Subependymal giant cell astrocytomas (SEGA) may lead to significant neurological morbidity in children diagnosed with tuberous sclerosis complex (TSC). Surgical resection is warranted for SEGAs demonstrating continuous growth, causing hydrocephalus and increased intracranial pressure. mTOR inhibitors (sirolimus and everolimus) are alternatives to surgery and have shown efficacy in stabilizing and shrinking SEGAs. Everolimus showed stronger evidence in efficacy, but its cost poses a limitation for this treatment among patients from low-middle income countries. We explored sirolimus as a potentially more cost-effective alternative in our setting. We present a 10-year-old Filipino child with TSC admitted due to headache, vomiting, and increased sleeping time. Neuroimaging revealed large bilateral SEGAs involving the frontal horns and foramina of Monro, causing moderate obstructive hydrocephalus. Surgical excision was offered, but parents opted for medical treatment. Bilateral posterior parietal ventriculoperitoneal shunts were inserted to decrease intracranial pressure. Due to the cost of everolimus, the patient was started on sirolimus at 1mg/m<sup>2</sup>/day. Imaging done 6 months after initiating therapy demonstrated significant decrease in size of both SEGAs (right: 82.5%, left: 64.1%). Sirolimus levels were maintained at 15.7ng/ml and minimal elevations on cholesterol and triglyceride levels were observed and treated with simvastatin. Results of this case and review of related data suggest that sirolimus can be used as a conservative approach in inducing regression of large bilateral SEGAs, and an affordable alternative to everolimus for pediatric TSC patients from low-middle income countries. Prospective studies and clinical trials are needed to further establish its efficacy, safety and cost-effectiveness in our setting.

#### LINC-18. FOLLOW-UP EVALUATION OF A WEB-BASED PEDIATRIC BRAIN TUMOR BOARD IN LATIN AMERICA

Mariel Rosabal Obando<sup>1</sup>, Diana S. Osorio<sup>2</sup>, Alvaro Lassaletta<sup>3</sup>, Andrés Morales La Madrid<sup>4</sup>, Ute Bartels<sup>5</sup>, Jonathan L. Finlay<sup>2</sup>, Ibrahim Qaddoumi<sup>6</sup>, Stefan Rutkowski<sup>1</sup>, and Martin Mynarek<sup>1</sup>;